Last reviewed · How we verify
quetiapine (Seroquel) XR — Competitive Intelligence Brief
marketed
Atypical antipsychotic
Dopamine D2 receptor, serotonin 5-HT2A receptor
Psychiatry
Small molecule
Live · refreshed every 30 min
Target snapshot
quetiapine (Seroquel) XR (quetiapine (Seroquel) XR) — Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.. Quetiapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| quetiapine (Seroquel) XR TARGET | quetiapine (Seroquel) XR | Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc. | marketed | Atypical antipsychotic | Dopamine D2 receptor, serotonin 5-HT2A receptor | |
| placebo with Clozapine | placebo with Clozapine | Shanghai Mental Health Center | marketed | Atypical antipsychotic | Dopamine D2 receptor, Serotonin 5-HT2A receptor | |
| Oral Olanzapine | Oral Olanzapine | Eli Lilly and Company | marketed | Atypical antipsychotic | Dopamine D2 receptor, Serotonin 5-HT2A receptor | |
| Quetiapine or Risperidone + Aripiprazole | Quetiapine or Risperidone + Aripiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | marketed | Atypical antipsychotic | Dopamine D2 receptor, serotonin 5-HT2A receptor | |
| risperidone (Risperdal) | risperidone (Risperdal) | University of South Florida | marketed | Atypical antipsychotic | Dopamine D2 receptor, Serotonin 5-HT2A receptor | |
| Fluoxetine+Olanzapine | Fluoxetine+Olanzapine | University Health Network, Toronto | marketed | SSRI + atypical antipsychotic combination | Serotonin transporter (SERT), dopamine D2 receptor, serotonin 5-HT2A receptor | |
| full-dose olanzapine | full-dose olanzapine | Kaohsiung Kai-Suan Psychiatric Hospital | marketed | Atypical antipsychotic | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Atypical antipsychotic class)
- Shanghai Mental Health Center · 10 drugs in this class
- AstraZeneca · 6 drugs in this class
- Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
- Eli Lilly and Company · 4 drugs in this class
- Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
- Medical University of Vienna · 2 drugs in this class
- Organon and Co · 2 drugs in this class
- Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
- H. Lundbeck A/S · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- quetiapine (Seroquel) XR CI watch — RSS
- quetiapine (Seroquel) XR CI watch — Atom
- quetiapine (Seroquel) XR CI watch — JSON
- quetiapine (Seroquel) XR alone — RSS
- Whole Atypical antipsychotic class — RSS
Cite this brief
Drug Landscape (2026). quetiapine (Seroquel) XR — Competitive Intelligence Brief. https://druglandscape.com/ci/quetiapine-seroquel-xr. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab